Chemotherapy in patients with recurrent and progressive central neurocytoma
Autor: | Carla Carollo, Silvio Monfardini, M. Gardiman, Gianpietro Pinna, Alba A. Brandes, Bianca Guglielmi, Pietro Amistà, Daniela Danieli, Sergio Turazzi, Lorenzo Volpin |
---|---|
Rok vydání: | 2000 |
Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Cyclophosphamide medicine.medical_treatment Drug Administration Schedule chemistry.chemical_compound Antineoplastic Combined Chemotherapy Protocols medicine Central neurocytoma Humans Neurocytoma Antineoplastic Agents Alkylating Etoposide Chemotherapy Brain Neoplasms business.industry Cancer Middle Aged medicine.disease Antineoplastic Agents Phytogenic Magnetic Resonance Imaging Nitrogen mustard Surgery Radiation therapy Treatment Outcome Oncology chemistry Chemotherapy Adjuvant Female Cisplatin Neoplasm Recurrence Local business medicine.drug |
Zdroj: | Cancer. 88:169-174 |
ISSN: | 1097-0142 0008-543X |
DOI: | 10.1002/(sici)1097-0142(20000101)88:1<169::aid-cncr23>3.0.co;2-7 |
Popis: | BACKGROUND Recurrent central neurocytoma is very rare and to the authors' knowledge data regarding its response to chemotherapy currently are not available. METHODS Three patients with progressive neurocytoma received chemotherapy after their informed consent was obtained. Disease recurred in two patients after surgery and radiotherapy and in one patient after surgery. The treatment regimen was comprised of etoposide, 40 mg/m2/day, for 4 days; cisplatin, 25 mg/m2/day, for 4 days; and cyclophosphamide, 1000 mg/m2, on Day 4; this cycle was repeated every 4 weeks. RESULTS Stabilization of disease was observed in 2 patients and complete remission was observed in 1 patient; at last follow-up, these responses had been maintained for 15 months, 18 months, and 36 months, respectively. CONCLUSIONS In this small series, this therapeutic regimen led to long term disease reduction, and merits further study. Cancer 2000;88:169–74. © 2000 American Cancer Society. |
Databáze: | OpenAIRE |
Externí odkaz: |